Business Standard

Sunday, December 22, 2024 | 06:39 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

AstraZeneca seeks US emergency approval for Covid-19 antibody cocktail

The cocktail can supplement vaccines for people who haven't mounted a strong response to the shots -- or to protect those who couldn't be immunized

Photo: Bloomberg
Premium

Photo: Bloomberg

Marthe Fourcade | Bloomberg
AstraZeneca Plc submitted its antibody cocktail for U.S. emergency approval to prevent Covid-19 infection as therapeutic options for the pandemic broaden beyond vaccination.

It’s the first regulatory filing for the medicine, which was 77% effective in preventing symptomatic Covid in a clinical trial that included patients with high-risk factors for severe infection. 

The cocktail can supplement vaccines for people who haven’t mounted a strong response to the shots -- or to protect those who couldn’t be immunized. The news comes just days after Merck & Co. fueled optimism that it will soon have the first Covid pill. Both treatments could offer a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in